What Are Biosimilars?

Biosimilars are copy versions of biological products whose patents have expired. The manufacture of biosimilars which is complicated leads to the high barriers to enter the industry. However, the investment for the development of biosimilars is much lower at the early stage, as the original biologics can be the reference drugs. Thus, the prices of biosimilars could be more flexible after the products launch and are the benefits of expanded market penetration rate.

more
WHO/UCAB Project

In order to accelerate the penetration of necessary drugs, the WHO-supported UCAB organized pharmaceutical companies from various regions of the world to co-develop biosimilars. By sharing the development results and reducing waste on the repeated R&D, biosimilars can be supplied to the global market with affordable prices in the future.

more
Hazard of Respiratory Syncytial Virus

Respiratory syncytial virus (RSV) is the main cause of bronchiolitis and pneumonia in infants. It especially causes an extremely high risk of hospitalization and death resulted from complications in premature babies. Palivizumab is the only monoclonal antibody that can be applied to prevent RSV infection.

more